There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
NCT05661084
Recruiting
This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.
Gender:
All
Ages:
55 years and above
Trial Updated:
04/02/2023
Locations: Hinda and Arthur Marcus Institute for Aging Research, Boston, Massachusetts
Conditions: Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Register for Updates
Dietary Intervention to Mitigate Adverse Consequences of Night Work
NCT04868526
Recruiting
The goal of this clinical trial is to test whether our dietary intervention can prevent or lessen the negative health effects of night shift work in healthy participants. Participants will: complete 2 inpatient stays be provided with identical meals have frequent blood draws provide urine, saliva, stool and rectal swab samples
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
03/30/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Dietary Habits
Register for Updates
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
NCT04363697
Recruiting
This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2023
Locations: TIMI Study Group, Boston, Massachusetts
Conditions: Acute Heart Failure, Heart Failure
Register for Updates
The Effect of Pediatric Patient Temperament on Postoperative Outcomes
NCT04224324
Recruiting
The goal of this study is to determine if preoperative temperament is associated with postoperative pain, emergence agitation, emotional and behavioral changes, and overall parent satisfaction. This is a prospective observational study to assess preoperative temperament in pediatric patients undergoing tonsillectomy and adenoidectomy, gather demographic data, intraoperative data regarding surgical and anesthetic technique, and collect immediate postoperative data to assess pain, emergence agitat... Read More
Gender:
All
Ages:
Between 2 years and 7 years
Trial Updated:
03/28/2023
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Emergence Delirium, Temperament
Register for Updates
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
NCT04895995
Recruiting
The treatment of generalized anxiety disorder (GAD) in an accessible manner represents an unmet need for those with cardiovascular disease (CVD), given that patients with CVD experience numerous barriers for in-person treatment engagement. The research plan for the proposed pilot project will entail: (1) open study of the acceptability of the digital intervention (N=5), followed by (2) recruitment and randomization of 90 individuals with a history of acute CVD events and clinical levels of GAD s... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Boston University, Boston, Massachusetts
Conditions: Anxiety Disorders, Cardiovascular Diseases, Anxiety, Health Behavior
Register for Updates
Development of a Telehealth-delivered Peer Navigation and Coping Skills Intervention to Increase PrEP Use in Young Black MSM
NCT05769270
Recruiting
This proposal seeks to adapt an existing peer navigation protocol (by adding coping skills and using telehealth) to be feasible, acceptable, and capable of supporting both PrEP uptake and P-E adherence for YBMSM ages 15-24.
Gender:
Male
Ages:
Between 15 years and 24 years
Trial Updated:
03/27/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hiv, Sexual Behavior
Register for Updates
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
NCT05076591
Recruiting
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
NCT04053673
Recruiting
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. As a PARP7 inhibitor RBN-2397 is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Solid Tumor, Adult
Register for Updates
Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
NCT04015596
Recruiting
This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children. To accomplish this goal, the investigators will conduct a double-blind, randomized, placebo-controlled trial of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID) in participants diagnosed with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). This research fills a gap in the empirical evidenc... Read More
Gender:
All
Ages:
Between 6 years and 15 years
Trial Updated:
03/23/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: PANDAS, Anxiety Disorder, Autoimmune Diseases, Obsessive-Compulsive Disorder
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
All
Ages:
All
Trial Updated:
03/23/2023
Locations: Clinical Trial Site, Boston, Massachusetts
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
NCT05799222
Recruiting
This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/22/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Overweight, PreDiabetes, Diabetes Type 2, Obesity
Register for Updates
A Study of the Effects of Oxytocin in Adults With Obesity and Binge-eating Disorder
NCT05664516
Recruiting
This study evaluates the impact of intranasal oxytocin vs placebo in patients with obesity and binge eating disorder with obesity. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes [weight loss, reduction in bingeing frequency], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 w... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
03/22/2023
Locations: Neuroendocrine Unit Research Center, Boston, Massachusetts
Conditions: Binge-eating Disorder
Register for Updates